Aquestive Therapeutics, Inc. $AQST Position Raised by Profund Advisors LLC

Profund Advisors LLC raised its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 497.9% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 195,758 shares of the company’s stock after acquiring an additional 163,019 shares during the period. Profund Advisors LLC owned about 0.16% of Aquestive Therapeutics worth $906,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Bratton Capital Management L.P. bought a new stake in shares of Aquestive Therapeutics in the second quarter worth $40,813,585. BlackRock Inc. bought a new position in Aquestive Therapeutics in the second quarter valued at $33,569,000. Bank of America Corp DE bought a new position in Aquestive Therapeutics in the second quarter valued at $6,941,000. Blue Owl Capital Holdings LP acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at $3,923,000. Finally, Wasatch Advisors LP increased its stake in Aquestive Therapeutics by 57.8% in the 2nd quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock valued at $5,765,000 after buying an additional 507,527 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AQST. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, October 16th. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Aquestive Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.60.

Aquestive Therapeutics Price Performance

AQST stock opened at $3.88 on Wednesday. Aquestive Therapeutics, Inc. has a 1-year low of $2.93 and a 1-year high of $6.85. The business’s 50 day simple moving average is $4.62 and its 200 day simple moving average is $4.20.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $7.56 million during the quarter, compared to analyst estimates of $11.02 million. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.50 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Daniel Barber sold 25,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the completion of the sale, the chief executive officer owned 627,317 shares of the company’s stock, valued at approximately $2,647,277.74. The trade was a 3.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the transaction, the insider owned 235,689 shares in the company, valued at $1,230,296.58. This trade represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 58,750 shares of company stock worth $271,675. 6.81% of the stock is owned by corporate insiders.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.